



NEURAL THERAPEUTICS INC.

**INTERIM MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS FOR THE THREE MONTHS ENDED
OCTOBER 31, 2024**

December 30, 2024

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

The following interim management's discussion and analysis ("MD&A") of the financial condition and results of the operations of Neural Therapeutics Inc. ("Neural", or the "Company" constitutes management's review of the factors that affected the Company's financial and operating performance for the three months ended October 31, 2024, and 2023. This MD&A has been prepared in compliance with the requirements of National Instrument 51-102 – Continuous Disclosure Obligations. This discussion should be read in conjunction with the audited financial statements of the Company for the year ended July 31, 2024, together with the notes thereto. Results are reported in Canadian dollars, unless otherwise noted. The unaudited condensed consolidated interim financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"). Information contained herein is presented as of December 30, 2024, unless otherwise indicated.

For the purposes of preparing this MD&A, management, in conjunction with the Board of Directors, considers the materiality of information. Information is considered material if: (i) such information results in, or would reasonably be expected to result in, a significant change in the market price or value of the Company's common shares; (ii) there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision; or (iii) it would significantly alter the total mix of information available to investors. Management, in conjunction with the Board of Directors, evaluates materiality with reference to all relevant circumstances, including potential market sensitivity.

Neural's business financial condition and results of operations may be further negatively affected by economic and other consequences from Russia's military action against Ukraine and the sanctions imposed in response to that action in late February 2022. Neural expects any direct impacts, of the pandemic and the military action in Ukraine, to the business to be limited; however, the indirect impacts on the economy and on the pharmaceutical industry could negatively affect the business and may make it more difficult for Neural to raise equity or debt financing. There can be no assurance that Neural will not be impacted by adverse consequences that may be brought about on its business, results of operations, financial position, and cash flows in the future.

Neural's board of directors approved the release of this MD&A on December 30, 2024.

FORWARD-LOOKING INFORMATION

Certain statements and information contained herein may constitute "Forward-Looking Statements" and "Forward-Looking Information," respectively, under Canadian securities legislation. Generally, Forward-Looking Information can be identified by the use of Forward-Looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify Forward-Looking Statements or Information. The Forward-Looking Statements are not historical facts but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these Forward-Looking Statements.

Forward-Looking Statements regarding Neural are based on Neural's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such Forward-Looking Statements or Forward-Looking Information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Statements and Forward-Looking Information. Filament will not update any Forward-Looking Statements or Forward-Looking Information that are incorporated by reference herein, except as required by applicable securities laws. For more information on Forward-Looking Information, please refer to the section entitled "*Cautionary Note Regarding Forward-Looking Statements*" of this MD&A.

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

CORPORATE OVERVIEW

Neural Therapeutics Inc. ("**Neural**") is a drug-discovery company focusing on plant-based active substances with the goal of delivering beneficial, over-the-counter dietary supplements and psychedelic-based therapeutic medicines to treat serious mental ailments where no effective significant treatment is available today. Neural's key ingredient is mescaline derived from sustainable legal and cultivated sources, including the San Pedro cactus. Neural is working to identify where plant-based traditional-medicine has proven to be effective and capitalize on the development of pharmaceutical and nutraceutical path to market that is compliant with applicable regulations.

Neural is in the business of developing products from plants containing psychedelic components that have a historical high record of safety and therapeutic value. Since inception, Neural has primarily focused on the discovery and development of cacti containing the psychoactive compound mescaline. Since its inception in early 2020, Neural has been focused on filling the scientific literature gap that exists between recreational/religious niche applications and main-stream pharmaceutical acceptance. Recognizing that the pathway to full acceptance while dealing with a controlled substance has inherited challenges and rewards. Neural is well positioned to be the world leading expert in products derived from cacti of the *Echinopsis* genus.

On May 23, 2023, Neural became an unlisted reporting issuer in the Provinces of British Columbia, Alberta and Quebec, pursuant to a plan of arrangement (the "**Plan of Arrangement**") between the Company and Vertical Peak Holdings Inc. ("**Vertical Peak**"), more particularly described in the management information circular of Vertical Peak and the amended and restated arrangement agreement dated February 24, 2023 ("**Arrangement Agreement**") between Neural and Vertical Peak available on Neural's profile on www.sedarplus.ca.

As at December 30, 2024, the members of Company's management and Board of Directors consisted of:

Name	Position
John Durfy	Chairman of the Board
Ian Campbell	Director, Chief Executive Officer and Secretary
Omar Gonzalez	Chief Financial Officer
Alex Storcheus	Director
Eran Ovadya	Director
Colin McLelland	Director
Carlos Davidovich	Director

Q1 ENDED OCTOBER 31, 2024 - FINANCIAL AND BUSINESS HIGHLIGHTS*Letter of Intent with CWE European Holdings Inc.*

On October 3, 2024, the Company has signed a non-binding letter of intent ("**LOI**") to acquire an interest in CWE European Holdings Inc., ("**CWE**" or "**HANF**") a prominent hemp-based product retailer in Germany. CWE owns and operates both physical and online stores, with 12 locations in the State of Bavaria in Germany under the brand name "HANF". Notably, CWE's private label products account for 50% of its offline retail sales.

Under the terms of the LOI, Neural and CWE intend to enter into an agreement or series of agreements ("**Definitive Agreement**") that will give Neural an option to acquire an interest in CWE as follows:

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

- **Series A Option** - Neural will have an option to acquire approximately 36% equity interest in CWE in by issuing an aggregate of 80,000,000 common shares in the capital of Neural ("**Neural Shares**"), determined using an exchange ratio ("**Exchange Ratio**") of four Neural Shares for each corresponding share in the capital of CWE ("**CWE Share**");
- **Series B Option** - Neural will have an option to acquire the remaining 64% equity interest in CWE, subject to the same Exchange Ratio, with the exact number of Neural securities to be determined in the Definitive Agreement.

The LOI is intended as an expression of the mutual intention of the parties to proceed towards settling the Definitive Agreement and is not a binding contract or commitment to consummate the transactions set out in the LOI. Completion of the transactions described herein are subject to a number of conditions, including but not limited to, execution of the Definitive Agreement, completion of satisfactory due diligence, CSE acceptance and receipt of requisite regulatory approvals. Where applicable, the proposed transaction cannot close until the required shareholder approvals, and any ancillary matters thereto, are obtained. There can be no assurance that the transactions will be completed as proposed or at all.

BUSINESS DESCRIPTION

Neural is a Canadian-based ethnobotanical drug discovery/development company focused on developing products and conducting research with psychoactive plants. The first being San Pedro a cactus containing mescaline, a naturally occurring hallucinogen that is found in certain psychoactive plants and has been in continuous use for at least 5,700 years in South America, namely Peru, Bolivia and Colombia. Neural intends to collect and aggregate data over the next 12 months to refine its pharmaceutical drug development and natural health product pipeline. To date, Neural's activities to develop its business focused on product and intellectual property development, conducting initial research and development to guide its drug development strategy, and various corporate and business development activities. Neural's registered office and corporate headquarters are in Canada, but Neural may conduct its research and development efforts, including, cultivation, extraction, processing, product manufacturing, pre-clinical and clinical trials, in jurisdictions outside of Canada, United States and Peru. Neural only works with parties who hold or will obtain all necessary permits and licenses to operate in the jurisdictions where they are located during the time they are engaged by Neural.

Neural is a development stage company and has not earned any revenue to date and has focused on developing its business in two main platforms as follows: (1) pharmaceutical pathway; and (2) nutraceutical pathway, each of which are briefly described below.

Pharmaceutical Pathway (with mescaline)

Neural is taking steps to create mescaline-based products to compete in the emerging psychedelics market. Neural is in the process of developing a line of *San Pedro*-derived products that will help with various health objectives. The initial research and development work will focus on the active ingredients' reproducibility by means of molecular and DNA analysis, identity testing, specifications and formulation. As noted above, Neural entered into agreement with Cayetano University to assist with the fundamental research and development activities to enable submission of an investigative new drug ("**IND**") application.

The second fundamental research and development activity is preparation for the initial safety studies (being pre-clinical and toxicology tests to that the standard of reasonable expectation of safety for human consumption is met). Neural is in the process of securing relationships with various contract research organizations ("**CRO**") to assist with those efforts. At present, Neural is in advanced discussions with several potential CROs in various jurisdictions. In connection with the preparation to conduct the studies, Neural also intends to establish a relationship with manufacturing partners and to test its supply chain,

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

extraction, and product development capabilities for such mescaline containing products. The efforts to commence these studies are ongoing and are subject to Neural securing the contractual relationships with parties which hold necessary permits and have the capabilities to conduct such research and development efforts.

As a result of its planned initial pre-clinical and clinical research efforts, Neural intends to carefully select specific drug candidates and diseases that it believes offer the greatest opportunity for therapeutic efficacy and commercial success. In consultation with various academic institutions, researchers, clinicians, and psychedelic industry opinion leaders, the goal of Neural's pharmaceutical division is to design clinical development programs that have clearly defined and achievable endpoints, that are expected to increase Neural's chance of commercial success.

Nutraceutical Pathway

In parallel with pursuing clinical research studies, Neural aims to investigate utilization of the pulp fiber from the cactus to manufacture products that would be used for weight loss supplements, dietary supplements, dietary fiber and diabetic food. Neural intends to partner with companies which have nutraceutical product manufacturing capabilities, to develop such products and secure required regulatory approvals to market such products in the United States and Canada. Neural is, at present, among very few companies that would offer cactus-based supplement products and, to Neural's knowledge, the only company to offer mescaline-free dietary supplements and NHPs that are based on the San Pedro cactus, and Neural believes that such position will give it an early-mover advantage in this regard. Demonstrating product safety at pre-determined levels of dosage is an integral part of the regulatory process to register its products with the FDA and Health Canada.

SIGNIFICANT TRANSACTIONS AND FINANCINGS

As of July 31, 2024, the Company has received \$54,985 for the ongoing private placement of Neural Shares and recorded it in shares to be issued.

Other than noted above, there were no significant transactions and or financing activities during the three months ended October 31, 2024 .

COMMITMENTS AND CONTINGENCIES**Securities Issuable Pursuant to the Campbell Agreement**

In accordance with the terms of the Campbell Agreement subject to the achievement of certain milestones, Neural agreed to issue to Ian Campbell, Chief Executive Officer of Neural the following:

- (i) Upon the closing of the Seed Financing, that number of common shares equal to 1.5% of the issued and outstanding capital of the Corporation as constituted at the closing of the seed financing for no additional consideration
- (ii) Upon the:
 - a. closing of the Seed Financing; and
 - b. achievement of certain milestones by Mr. Campbell and Neural agreed to by Mr. Campbell and the board of directors of Neural ("**Board**")A number of Neural Shares equal to an aggregate of 2.0% of the issued and outstanding capital of Neural as constituted at closing of the Seed Financing, released to Mr. Campbell in equal parts on a quarterly basis, in arrears, for a period of two (2) years from the date of closing the Seed Financing provided that Campbell Agreement continues in full force; and
- (iii) Upon the achievement of certain milestones by Mr. Campbell and Neural, agreed to by Mr. Campbell and the Board; stock options equal to 2% of the issued and outstanding capital of

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

immediately prior to Neural listing its common shares on a recognized stock exchange or trading quotation system ("**Listing**"). Such stock options shall be exercisable at a price that is a 20% premium to the last financing price whereby shares of the Corporation were issued immediately prior to Listing, and shall vest in equal amounts, every six (6) months over three (3) years from their date of granting, or as required under applicable securities legislation and regulation, and will be subject to the terms of any stock option plan adopted by the Corporation.

Campbell Agreement provides that the process for satisfaction of the issuances of securities set out in the Campbell Agreement summarized above shall be determined by mutual agreement between Neural and Mr. Campbell and such securities have not been issued as of the date hereof.

Securities Issuable Pursuant to the FMI Capital Advisory Inc. ("FMICA") Agreement

In accordance with the terms of the FMICA Agreement dated December 17, 2021, Neural agreed to:

- Issue to FMICA an initial equity fee ("**Equity Fee**") in a form of Neural Shares equal to 5% of the issued and outstanding Neural Shares upon Neural completing a Seed Financing in the minimum amount of \$500,000, which was issued on February 2, 2022;
- Issue to FMICA an initial fee ("**Initial Fee**") in a form of Neural Shares equal to 5% of the issued and outstanding Neural Shares upon Neural completing a Listing; and
- Pay FMICA a monthly advisory fee equal to \$10,000, payable monthly in arrears commencing from September 1, 2021 until the earlier of: i) termination (30-day notice); ii) 4 months following Listing. As of April 30, 2024, the Company has accrued \$50,000 for advisory fees.

RSU Issuances

In accordance with the terms of an advisory agreement with a former officer of Neural, Neural committed to issue 366,667 shares. Terms and conditions of this agreement are yet to be finalized.

Costs relating to the Plan of Arrangement

In accordance with the terms of the Arrangement Agreement, Neural agreed that it will be responsible for all costs associated with the Plan of Arrangement, the Vertical Peak shareholder meeting, and the preparation of the related documentation.

SELECTED QUARTERLY INFORMATION

The following is a summary of the Company's quarterly financial results for the eight most recently completed quarters to October 31, 2024:

For the quarter ended:	October 31, 2024 \$	July 31, 2024 \$	April 30, 2024 \$	January 31, 2024 \$
Net loss	100,604	209,031	122,672	176,468
Loss per share from operations	0.00	0.00	0.00	0.00

For the quarter ended:	October 31, 2023 \$	July 31, 2023 \$	April 30, 2023 \$	January 31, 2023 \$
Net loss	157,859	183,398	293,192	220,758
Loss per share from operations	0.00	0.00	0.01	0.01

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

DISCUSSION OF OPERATIONS**Sales Revenue and Gross Profit**

Neural did not have revenues or gross profit during the three months ended October 31, 2024.

Operating Expenses

Operating expenses during the three months ended October 31, 2024 were \$100,604 compared to \$157,859 during the corresponding three months ended October 31, 2023. This decrease was primarily due to the following:

- A decrease in salaries, wages and benefits of \$244 as a result deferral of Neural's management team's salaries agreed to by such members of the management team;
- A decrease in consulting fees of \$10,9602 as a result of fewer contracting consultants to assist with the business development, preparation for public listing (including the Plan of Arrangement) and certain scientific activities;
- An increase in professional fees of \$1,769, as the previous corresponding year included certain one-time costs related to the formative activities of the Company and refocusing of the overhead on preparation for a potential public listing (including the Plan of Arrangement);
- A decrease of \$4,640 in general and administrative fees, mainly as a result of a decrease in general and administrative expenses incurred in the year; and
- A decrease of \$56,956 in research expenses, as a result of a decrease in consultants to assist with the research activities, as well as salaries wages and benefits allocations expenses.

LIQUIDITY AND CAPITAL RESOURCES

Neural's financial success is reliant on management's ability to identify and evaluate suitable growth and acquisition opportunities and maximizing the potential of these opportunities. In order to fund future growth opportunities and to corporate overhead, Neural may seek additional financing through debt or equity offerings. Any equity offering will result in dilution to the ownership interests of Neural's shareholders and may result in dilution to the value of such interests.

Liquidity risk is the risk that Neural will not have sufficient cash resources to meet its financial obligations as they come due. The ability of Neural to continue as a going concern is dependent on its ability to obtain funding, manage cash flows, restructure borrowings and recover funds loaned to borrowers that have currently been provided against or recover collateral that secured those loans. There is significant uncertainty as to whether Neural will be able to continue as a going concern and therefore, whether it will continue its normal business activities and realize its assets and extinguish its liabilities in the normal course of business and at the amounts stated in the financial statements. These financial statements do not include adjustments relating to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessary should Neural not continue as a going concern. In the short term, the continued operations of Neural may be dependent upon its ability to obtain additional financing. Without this additional financing, Neural may be unable to meet its obligations as they come due. There can be no certainty that Neural can obtain these funds, in which case any investment in Neural may be lost.

As at October 31, 2024, Neural had working capital deficiency of \$303,273 (July 31, 2024 – working capital deficiency of \$210,169), had accumulated losses of \$4,237,346 (July 31, 2024 - \$4,136,742). Neural expects to be able to meet its financial obligations in the near future but intends to undertake additional capital raises and seek deferral of forgiveness of some of its accrued liabilities to remedy the working capital deficiency.

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

Cash Flow Operating activities

Net cash used in operating activities during the three months ended October 31, 2024, totaled \$998, compared to \$258,572 for the same period in 2023. This significant decrease was primarily driven by the reduction of certain accounts payable and accrued liabilities, offset by the reclassification of specific payables as long-term liabilities. Additionally, the decrease in business activity and preparations for a public listing contributed to the lower cash usage during the period.

Financing activities

During the three months ended October 31, 2024, net cash generated in financing activities totaled \$nil, compared \$142,595 in the corresponding period in 2023. The decrease was primarily due to a reduction in proceeds from the issuance of securities.

Foreign currency exchange risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the foreign exchange rates. Neural enters into foreign currency purchase transactions and has assets and liabilities that are denominated in foreign currencies and thus is exposed to the financial risk fluctuations arising from changes in foreign exchange rates and the degree of volatility of these rates. Neural does not currently use derivative instruments to reduce its exposure to foreign currency risk.

An increase (decrease) of 10% in the currency exchange rate of the Canadian dollar versus US dollar would have impacted Neural net loss by \$1,000 (July 31, 2024 - \$nil), reflecting Neural's exposure to currency exchange rate fluctuations.

PROMISSORY NOTE

As at October 31, 2024, the Company has a promissory note of \$11,596 (July 31, 2024 - \$11,238) provided by a company controlled by a consultant of the Company. The outstanding balance is secured, bears interest annual rate of 13% and is due on January 31, 2025. The promissory note included principal amounts of \$11,000 (July 31, 2024 - \$11,000) and interest accrued of \$596 (July 31, 2024 - \$238).

CAPITAL MANAGEMENT

Neural includes cash and cash equivalents and shareholders' equity, comprising issued common shares, contributed surplus and deficit, in the definition of capital. Neural manages its capital structure and makes adjustments to it, based on the funds available to Neural. Neural's objectives when managing its capital are to safeguard Neural's ability to continue as a going concern in order to support ongoing initiatives, to provide sufficient working capital to meet its ongoing obligations, and to pursue potential acquisitions.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of Neural, is reasonable. Neural is not subject to externally imposed capital requirements. Neural has not paid or declared any dividends since the date of incorporation, nor are any contemplated in the foreseeable future.

OFF-BALANCE SHEET ARRANGEMENTS

Neural has not entered into any off-balance sheet arrangements.

PROPOSED TRANSACTIONS

Neural is not a party to any agreement for proposed transactions.

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

SUBSEQUENT EVENTS*Conditional Approval to List on the CSE*

Further to its press release dated May 8, 2024, Neural received conditional approval ("**Conditional Approval**") to Neural Shares on the CSE, contingent upon fulfilling specific requirements such as completing financing of at least \$500,000 and filing the documentation that may be required by the CSE. Neural remains committed to satisfying these conditions promptly and expects to secure final approval in due course. The terms of the Concurrent Financing (as such term is defined in the Neural press release dated May 8, 2024) remain unchanged and Neural continues to work toward completing the Concurrent Financing. Listing is not conditional on closing of the transactions between CWE and Neural described herein, and the parties do not expect that the Definitive Agreement will be signed, or that the transactions between CWE and Neural will be completed prior to listing.

Deferral Agreements, Consultant Agreement and HCA Termination Agreement

On November 15, 2024, Neural entered into waiver and payment deferral agreements ("**Deferral Agreements**") with Ian Campbell, CEO of Neural, Humber Capital Advisors Inc. ("**HCA**"), a company that is owned by John Durfy, Chairman of Neural and certain arm's length parties (collectively "**Creditors**"), which resulted in a deferral of certain accounts payable and accrued liabilities of an aggregate of \$691,318 ("**Deferred Amount**"). Pursuant to the terms of the Deferral Agreements, the Deferred Amount was deferred until the date ("**Deferral Trigger Date**") that is the earlier of: (a) January 15, 2026; and (b) the Company completing a financing for gross proceeds of no less than \$400,000 following a successful listing on a recognized stock exchange in Canada ("**Listing**"), which for greater clarity, excludes the financing that is expected to be completed in connection with or immediately prior to such Listing. Following entry into the Deferral Agreements, the Creditors entered into agreements to assign approximately \$551,318 of the Deferred Amount to an unrelated third party.

On November 15, 2024, the Company entered into an agreement to replace the employment agreement with Ian Campbell, CEO of Neural with a consulting agreement ("**Campbell Consulting Agreement**"), which provides for payment of a fee of \$2,000 per month on a go forward basis. Pursuant to the Campbell Consulting Agreement, Ian Campbell will continue to serve as the Chief Executive Officer, Secretary and Director of the Neural.

On November 15, 2024, the Company agreed to terminate the consulting agreement with HCA ("**HCA Termination Agreement**"). John Durfy will continue to serve as a Chairman of the Board of Neural.

On November 15, 2024 Neural agreed to issue 21,467,163 common share purchase warrants (each a "**Warrant**"), as follows: (a) 1,381,426 Warrants to Ian Campbell in connection with the execution of the Campbell Consulting Agreement; (b) 6,715,967 Warrants to John Durfy, in connection with the execution of the HCA Termination Agreement; (c) 9,120,001 Warrants in connection with consulting agreements entered into with third parties and (d) 4,249,769 Warrants to settle payables of \$4,125 with an unrelated party. Each Warrant will be exercisable into one common share in the capital of Neural ("**Neural Shares**") at a price of \$0.05 per Neural Share for a period of three years from the date of issuance, subject to acceleration by the Company giving at least 30 days' notice if the Neural Shares trade at a volume-weighted average price of \$0.15 or higher for a period of at least 10 consecutive trading days. The Warrants have not yet been issued by Neural and further updates in regard to the issuance date will be announced by way of press release.

CWE LOI Extensions

On November 15, 2024, Neural and CWE agreed to amend CWE LOI to extend the deadline to enter into Definitive Agreement to December 31, 2024.

On December 16, 2024, Neural and CWE agreed to amend CWE LOI to extend the deadline to enter into Definitive Agreement to January 31, 2025.

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

OUTSTANDING SHARE DATA

The table below sets out the number of Neural Shares and other securities convertible into Neural Shares outstanding as at each of July 31, 2024, and the date that appears on the title page of this document:

Description of Security	Outstanding as at October 31, 2024	Outstanding as of the date hereof
Neural Shares	65,771,712	65,771,712
Neural Warrants	5,546,667	5,546,667
Neural VP Warrants	2,000,000	2,000,000
Neural Broker Warrants	1,016,164	1,016,164
Neural Options ⁽¹⁾	-	-
Neural RSUs ⁽¹⁾	-	-
Rights	-	-

Notes:

(1) Neural Stock Option Plan and Neural RSU Plan were approved by Neural Shareholders at the January 6, 2023 meeting;

Related parties and key management

Key management includes Neural's directors, officers and any employees with authority and responsibility for planning, directing, and controlling the activities of an entity, directly or indirectly.

On March 31, 2024, Ian Campbell - Chief Executive Officer and Director of Neural, John Durfy – Chairman of Neural, and FMI Capital Advisory Inc. ("**FMICA**") each entered into a waiver and deferral agreements with Neural ("**Amended Deferral Agreements**"), pursuant to which each party agreed to defer the respective amounts outstanding to them as follows: \$283,510 (being the amount outstanding due to Mr. Campbell as of March 31, 2024), \$67,800 (being the amount outstanding due to Mr. Durfy as of March 31, 2024) and \$60,000 (being the amount outstanding due to FMICA as of March 31, 2024), until the earlier of: a) May 31, 2025; and b) Neural completing a financing for gross proceeds of no less than \$400,000 following Listing, excluding Series A Financing ("**Deferral Trigger Date**").

As at October 31, 2024 and July 31, 2024, the balance outstanding with them has been reclassified from current liabilities into long-term liabilities. Furthermore, each of Mr. Durfy and FMICA agreed to defer all the monthly amounts that will become payable under their respective agreements with Neural from March 31, 2024 to Deferral Trigger Date, which will become payable on the Deferral Trigger Date. Amount due to FMICA was classified as due to other party.

The following is a summary of the key management compensations for the year ended July 31, 2024 and 2023:

	2024	2023
Director fees (i)	\$ 22,500	22,500
Salaries (ii)	47,115	47,250
Marrelli Support Services Inc. (iii)	7,260	12,490
Total	\$ 76,875	82,240

- (i) During the three months ended October 31, 2024, the Company incurred \$22,500 (2023 - \$22,500), respectively, in consulting fees paid to a director of the Company. As at October 31, 2024, \$138,225 (July 31, 2024 - \$115,725) of which \$74,325 (July 31, 2024 - \$74,325) is included in due to related parties' long-term liabilities and \$63,900 (July 31, 2024 - \$41,400) is included in accounts payable and accrued liabilities.
- (ii) During the three months ended October 31, 2024, the Company incurred \$47,115 (2023 - \$47,250) in salaries, vacation accrual, and bonus expenses to Ian Campbell, CEO of the

NEURAL THERAPEUTICS INC.

Interim Management's Discussion & Analysis – Quarterly Highlights

For the three months ended October 31, 2024

(Expressed in Canadian Dollars)

Company. As of October 31, 2024, \$385,593 (July 31, 2024 - \$338,477) of which \$299,214 is included in due to related parties long-term liabilities and \$86,379 (July 31, 2024 - \$39,263) is included in accounts payable and accrued liabilities.

- (iii) During the three months ended October 31, 2024, the Company incurred \$7,260 (2023 - \$12,490), respectively for accounting and CFO services to Marrelli Support Services Inc. As at October 31, 2024, \$43,450 (July 31, 2024 - \$26,371) is included in accounts payable.

On May 31, 2023, the Company signed a waiver and payment deferral agreement ("**Deferral Agreement**") with Ian Campbell, CEO of the Company to defer the payment of amounts due to Mr. Campbell at the earlier of: a) 14 months from the date of the Deferral Agreement; and b) competing a financing for the gross proceeds of no less than \$400,000 following a successful listing on a stock exchange in Canada. On March 31, 2024, the Deferral Agreement was amended to the Amended Deferral Agreements (as described in Note 7(a) above), and as a result, as of October 31, 2024, \$373,539 (July 31, 2024 - \$373,539) was outstanding and included in due to related parties, of which \$299,214 (July 31, 2024 - \$299,214) was due to Mr. Campbell, and \$74,325 (July 31, 2024 - \$74,325) was owing to Mr. Durfy.

RISK FACTORS

An investment in the Company's securities is highly speculative and involves numerous and significant risks. Such investment should be undertaken only by investors whose financial resources are sufficient to enable them to assume these risks and who have no need for immediate liquidity in their investment. Prospective investors should carefully consider the risk factors that have affected, and which in the future are reasonably expected to affect, the Company and its financial position. Please refer to the section entitled "Risk Factors" in the Company's Annual MD&A for the fiscal year ended July 31, 2024, available on SEDAR+ at www.sedarplus.ca.

Management's Responsibility for Financial Information

Management is responsible for all information contained in this report. The financial statements have been prepared in accordance with International Financial Reporting Standards and include amounts based on management's informed judgments and estimates. The financial and operating information included in this report is consistent with that contained in the financial statements in all material aspects.

Management maintains internal controls to provide reasonable assurance that financial information is reliable and accurate, and assets are safeguarded.

The Board of Directors has approved the financial statements on the recommendation of the Audit Committee.

December 30, 2024

Ian Campbell - Chief Executive Officer

Omar Gonzalez - Chief Financial Officer